David Pelizzon Sells 16,300 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 16,300 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $24.74, for a total value of $403,262.00. Following the transaction, the director directly owned 6,881,464 shares of the company’s stock, valued at $170,247,419.36. The trade was a 0.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

OrthoPediatrics Stock Performance

NASDAQ KIDS opened at $23.32 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The stock’s 50 day simple moving average is $21.32 and its 200-day simple moving average is $18.62. The company has a market cap of $608.89 million, a PE ratio of -13.88 and a beta of 0.98. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. As a group, equities research analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

OrthoPediatrics News Roundup

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during its limited release. The system expands the company’s pediatric trauma and deformity portfolio and could create a long-term revenue and market-share opportunity, though management did not provide specific financial guidance. 3P Pediatric Plating Platform Hip System launch
• Positive Sentiment: Analyst sentiment remains favorable. Piper Sandler raised its target to $25, Needham lifted its target to $35, and BTIG increased its target to $29, while maintaining positive ratings. MarketBeat data shows a “Moderate Buy” consensus with an average target of $26.44.
• Positive Sentiment: Recent quarterly results exceeded expectations: OrthoPediatrics reported a loss of $0.26 per share versus the estimated loss of $0.30, while revenue of $70.51 million surpassed the $68.21 million consensus estimate. BlackRock and other institutional investors also recently initiated or expanded positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, but an invalid change figure makes the data unreliable and limits its usefulness for assessing short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholders associated with Squadron Capital and Jennifer N. Pritzker sold a combined 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The sales reduced their position by roughly 0.56%, leaving ownership of about 6.86 million shares. While modest relative to their remaining stake, repeated insider selling may weigh on investor sentiment, particularly with the stock near its 52-week high. SEC insider transaction filing

Institutional Trading of OrthoPediatrics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC raised its holdings in shares of OrthoPediatrics by 48.0% during the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after acquiring an additional 452,840 shares during the period. BlackRock Inc. purchased a new stake in shares of OrthoPediatrics in the second quarter valued at about $24,347,000. Vanguard Group Inc. grew its holdings in shares of OrthoPediatrics by 1.1% in the third quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after purchasing an additional 10,927 shares during the period. Granahan Investment Management LLC increased its position in OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after purchasing an additional 232,760 shares during the last quarter. Finally, Wasatch Advisors LP increased its position in OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after purchasing an additional 186,357 shares during the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on KIDS shares. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. BTIG Research upped their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Piper Sandler reiterated an “overweight” rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, Needham & Company LLC raised their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, OrthoPediatrics currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.